Genprex, Inc.

NasdaqCM:GNPX Voorraadrapport

Marktkapitalisatie: US$7.7m

Genprex Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Genprex's earnings have been declining at an average annual rate of -19.4%, while the Biotechs industry saw earnings growing at 19% annually.

Belangrijke informatie

-19.4%

Groei van de winst

7.2%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroein/a
Rendement op eigen vermogen-601.6%
Nettomargen/a
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Aug 16
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Jan 31
Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Oct 12
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14
We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27
We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

Opbrengsten en kosten

Hoe Genprex geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:GNPX Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-261313
31 Mar 240-281216
31 Dec 230-311318
30 Sep 230-311417
30 Jun 230-301416
31 Mar 230-281315
31 Dec 220-241212
30 Sep 220-241212
30 Jun 220-211110
31 Mar 220-19119
31 Dec 210-21129
30 Sep 210-19127
30 Jun 210-18117
31 Mar 210-19118
31 Dec 200-18117
30 Sep 200-15105
30 Jun 200-15105
31 Mar 200-14113
31 Dec 190-1192
30 Sep 190-12102
30 Jun 190-11102
31 Mar 190-14121
31 Dec 180-12111
30 Sep 180-1091
30 Jun 180-880
31 Mar 180-330
31 Dec 170-330
30 Sep 170-430
30 Jun 170-430
31 Mar 170-540
31 Dec 160-440

Kwaliteitswinsten: GNPX is currently unprofitable.

Groeiende winstmarge: GNPX is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: GNPX is unprofitable, and losses have increased over the past 5 years at a rate of 19.4% per year.

Versnelling van de groei: Unable to compare GNPX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: GNPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: GNPX has a negative Return on Equity (-601.59%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden